These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 1509293)

  • 1. Advances in the diagnosis and management of myeloma.
    Greipp PR
    Semin Hematol; 1992 Jul; 29(3 Suppl 2):24-45. PubMed ID: 1509293
    [No Abstract]   [Full Text] [Related]  

  • 2. Diagnosis and management of multiple myeloma and related disorders.
    Kyle RA
    Prog Hematol; 1986; 14():257-82. PubMed ID: 2418463
    [No Abstract]   [Full Text] [Related]  

  • 3. [Extramedullary plasmacytoma].
    Sucker C; Stockschläder M
    Dtsch Med Wochenschr; 2002 Jan; 127(4):153-5. PubMed ID: 11807659
    [No Abstract]   [Full Text] [Related]  

  • 4. Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.
    Hillengass J; Moehler T; Hundemer M
    Recent Results Cancer Res; 2011; 183():113-31. PubMed ID: 21509683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple myeloma: clinical features and indications for therapy.
    Dispenzieri A; Kyle RA
    Best Pract Res Clin Haematol; 2005; 18(4):553-68. PubMed ID: 16026737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance.
    Jerez A; Ortuño FJ; Osma Mdel M; Español I; González AD; Roldán V; de Arriba F; Vicente V
    Ann Med; 2009; 41(7):547-58. PubMed ID: 19634064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Multiple myeloma and chronic lymphocytic leukemia].
    Labardini-Méndez J; Alexanian R; Barlogie B
    Rev Invest Clin; 1997 May; 49 Suppl 1():28-33. PubMed ID: 9380986
    [No Abstract]   [Full Text] [Related]  

  • 9. [Diagnosis and therapy of multiple myeloma: current aspects].
    Betticher DC; Cerny T; Fey MF
    Schweiz Med Wochenschr; 1995 Mar; 125(11):541-51. PubMed ID: 7899848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A GEIL flow cytometry consensus proposal for quantification of plasma cells: application to differential diagnosis between MGUS and myeloma.
    Frébet E; Abraham J; Geneviève F; Lepelley P; Daliphard S; Bardet V; Amsellem S; Guy J; Mullier F; Durrieu F; Venon MD; Leleu X; Jaccard A; Faucher JL; Béné MC; Feuillard J;
    Cytometry B Clin Cytom; 2011 May; 80(3):176-85. PubMed ID: 21520405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple myeloma presenting as plasmacytoma of the base of the skull.
    Alegre A; Tomás JF; Pinilla I; Gil-Fernández JJ; Fernández-Rañada JM
    Am J Hematol; 1996 May; 52(1):60-1. PubMed ID: 8638614
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiple myeloma precursor disease: current clinical dilemma and future opportunities.
    Landgren O
    Semin Hematol; 2011 Jan; 48(1):1-3. PubMed ID: 21232652
    [No Abstract]   [Full Text] [Related]  

  • 13. Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: an immunohistochemical analysis.
    Morgan TK; Zhao S; Chang KL; Haddix TL; Domanay E; Cornbleet PJ; Arber DA; Natkunam Y
    Am J Clin Pathol; 2006 Oct; 126(4):545-51. PubMed ID: 16938662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical aspects of multiple myeloma].
    López Alvarez J; Sanz Marca A; Aboin Massieu FJ
    Rev Clin Esp; 1983 Nov; 171(3):165-74. PubMed ID: 6366936
    [No Abstract]   [Full Text] [Related]  

  • 15. [Silent onset of multiple myeloma. How to diagnosis and when to treat?].
    Bartl R
    Internist (Berl); 1986 Mar; 27(3):192-200. PubMed ID: 3086250
    [No Abstract]   [Full Text] [Related]  

  • 16. [IgM monoclonal gammopathy in plasmacytic neoplasms].
    Kraj M; Kopeć I; Rostkowska J; Pogłód R; Maj S
    Acta Haematol Pol; 1990; 21(2):153-65. PubMed ID: 2131715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important.
    Berenson JR; Yellin O
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):311-5. PubMed ID: 19717382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
    Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
    Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NCCN: Multiple myeloma.
    Traynor AE; Noga SJ;
    Cancer Control; 2001; 8(6 Suppl 2):78-87. PubMed ID: 11760563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?
    Mongkonsritragoon W; Kimlinger T; Ahmann G; Greipp PR
    Leuk Lymphoma; 1998 May; 29(5-6):577-84. PubMed ID: 9643571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.